Table 1. Clinical characteristics between the culture-positive and the negative groups in the prostate through lower urinary localization test after TRPB.
| Variables | Prostate culture | ||||
|---|---|---|---|---|---|
| Positive (%) | Negative (%) | P value | |||
| No. of patients | 20 | 85 | |||
| Age (mean ± SD), yr | 60.90 ± 10.89 | 62.88 ± 8.89 | 0.393 | ||
| Mean follow-up, mon | 7.05 ± 3.24 | 7.84 ± 3.17 | 0.323 | ||
| Prostate volume, mL | 47.65 ± 28.42 | 47.41 ± 21.08 | 0.966 | ||
| Pre-biopsy PSA, ng/mL | 9.54 ± 5.70 | 7.89 ± 5.60 | 0.240 | ||
| Post-biopsy PSA, ng/mL | 9.63 ± 8.08 | 7.59 ± 4.93 | 0.291 | ||
| Pre-biopsy PSA density, ng/mL/cc | 0.22 ± 0.12 | 0.20 ± 0.24 | 0.714 | ||
| Pre-biopsy sum of pain domain in NIH-CPSI | 1.95 ± 3.80 | 2.09 ± 3.54 | 0.606a | ||
| Post-biopsy sum of pain domain in NIH-CPSI | 1.80 ± 2.95 | 2.16 ± 3.44 | 0.891a | ||
| WBCs in pre-biopsy EPS (No/HPF) | 0.182 | ||||
| 0–4 | 12 (60) | 38 (44.7) | |||
| 5–15 | 5 (25) | 16 (18.8) | |||
| ≥ 16 | 3 (15) | 31 (36.5) | |||
| WBCs in post-biopsy EPS (No/HPF) | 0.326 | ||||
| 0–4 | 9 (45) | 38 (44.7) | |||
| 5–15 | 2 (10) | 20 (23.5) | |||
| ≥ 16 | 9 (45) | 27 (31.8) | |||
| Risk factors of infectious prostatitis after biopsy | |||||
| Presence of diabetes mellitus | 0.731b | ||||
| No | 18 (90) | 72 (84.7) | |||
| Yes | 2 (10) | 13 (15.3) | |||
| Recent history of AUR | 1.000b | ||||
| No | 20 (100) | 81 (95.3) | |||
| Yes | 0 (0) | 4 (4.7) | |||
| Fluoroquinolone exposure within 3 mon | 0.758b | ||||
| No | 17 (85) | 68 (80) | |||
| Yes | 3 (15) | 17 (20) | |||
TRPB = transrectal prostate biopsy, SD = standard deviation, PSA = prostate-specific antigen, NIH-CPSI = National Institutes of Health-Chronic Prostatitis Symptom Index, WBC = white blood cell, EPS = expressed prostatic secretion, HPF = high power field, AUR = acute urinary retention.
aNonparametric Mann-Whitney U analysis; bFisher's exact test.